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Background: Omega-3 fatty acids are associated with a lower risk of cardiovascular
disease (CVD) and with beneficial effects on CV risk factors. The albumin-creatinine ratio
(ACR) is a risk factor for CVD, all-cause mortality and accelerated glomerular filtration rate
(GFR) decline in the general population. We aimed to investigate the association between
n-3 PUFAS and ACR in heathy individuals with preserved GFR.
Design and Methods: The present cross-sectional analysis is part of the GAPP study,
a population-based cohort of healthy adults aged 25–41 years. Individuals with known
CVD, diabetes, or a BMI >35 kg/m2 were excluded. eGFR was calculated according to
the combined Creatinine/Cystatin C CKD-EPI formula. ACR was obtained from a fasting
morning urine sample. The Omega-3 Index (relative amount of EPA and DHA of total fatty
acids in %) was obtained from whole blood aliquots.
Results: Overall, 2001 participants (median age 37 years IQR 31; 40, 53% female) were
included in this analysis. Median Omega-3 Index was 4.59 (IQR 4.06; 5.25) and median
eGFR 111 ml/min/1.73 m2 (IQR 103; 118). Median ACR was 0.14 mg/mmol (IQR 0;
0.43). We found a significant inverse association of the Omega-3 Index with ACR (ratio
0.84, 95%CI 0.73–0.96; p = 0.011) which remained after comprehensive adjustment
(ratio 0.86, 95%CI 0.74–1.00; p = 0.048). No association of the Omega-3 Index with
eGFR was found. The adjusted difference in eGFR per 1-unit increase in Omega3-Index
was −0.21 (95%CI −0.76; 0.35; p = 0.47).
Conclusions: A higher Omega-3 Index was significantly associated with lower ACR in
this young and healthy population with preserved eGFR. Omega-3 fatty acids may exhibit
cardio- and nephroprotective effects in healthy individuals through modulation of ACR.
Keywords: omega-3-fatty acids, nutrition, prevention, population, kidney, albuminuria, albumin-creatinine ratio
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INTRODUCTION
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) include the
fish-derived eicosapentaenoic (EPA) and docosahexaenoic acid
(DHA) as well as alpha-linolenic acid (ALA) derived from plants.
Their beneficial effect on cardiovascular disease and risk factors
has been the focus of a multitude of experimental studies and
clinical investigations. Of note, they are associated with anti-
inflammatory as well as antithrombotic activity (1), they are likely
to improve endothelial dysfunction (2) and positively influence
cardiovascular risk factors like HbA1c (3), triglycerides (3), and
blood pressure (4).
Chronic kidney disease (CKD) and albuminuria as an
early marker for kidney damage are both well-established
cardiovascular risk factors (5, 6). In animal models dietary
supplementation with n-3 PUFAs slows the progression of
kidney disease and reduces urine albumin excretion as well as
renal inflammation and fibrosis (7, 8). In older community-
dwelling individuals, higher plasma PUFAs were associated
with a lower age-related decline in kidney function (9). Data
form interventional trials showed the potential of n-3 PUFA
supplementation to attenuate the progression of albuminuria in
individuals with type 2 diabetes and coronary heart disease (10).
Nevertheless, data from both observational and interventional
trials lack in healthy individuals free of cardiovascular
disease—where long-term prevention efforts may be
particularly effective.
We addressed these issues by investigating the associations of
whole blood n-3 PUFA levels (given as the Omega-3 Index) with




For this cross-sectional study, baseline data from the GAPP
study (genetic and phenotypic determinants of blood pressure
and other cardiovascular risk factors) were analyzed. The
GAPP study is an ongoing large population-based cohort
study, which investigates the determinants of BP and other
cardiovascular risk factors in young and healthy adults,
described elsewhere (11). In brief, from 2010 to 2013 all
inhabitants of the Principality of Liechtenstein in the given
age range were invited and 2,170 healthy adults aged 25–
41 years agreed to participate. Main exclusion criteria were
established cardiovascular disease, chronic kidney disease,
a BMI higher than 35 kg/m2, obstructive sleep apnea,
daily intake of non-steroidal anti-inflammatory medication
and diabetes.
From a total of 2,170 patients enrolled in the GAPP study, we
excluded participants on ACE-Inhibitors (n = 5), angiotensin-
receptor blockers (n = 22), diuretics (n = 9) as well as
the data sets with missing information on ethnicity (n =
136), creatinine or cystatin C values (n = 9). Because of
multiple exclusion criteria in one individual, 169 individuals
were excluded, resulting in a total of 2,001 participants for
this analysis.
The study protocol was approved by the local ethics
committee (Cantonal Ethics Commission of Zurich, Zurich,
Switzerland). Informed written consent was obtained from every
individual participant.
Blood Sampling and Whole Blood Fatty
Acid Composition
At baseline, venous whole blood samples were collected from
every participant after an overnight fast. The aliquoted cryotubes
where immediately stored at −80◦C (11), which has been shown
to not alter the n-3 levels measured (12), and underwent no
further freeze-thaw cycles. Whole blood fatty acids were analyzed
according to the high sensitivity-Omega-3 Index methodology,
initially described for erythrocyte samples (13). FA methyl esters
were generated from whole blood by acid transesterification
and analyzed by gas chromatography using a GC2010 Gas
Chromatograph (Shimadzu, Duisburg, Germany) equipped with
a SP2560, 100-m column (Supelco, Bellefonte, Pennsylvania,
USA) hydrogen as carrier gas. FAs were identified by comparison
with a standard mixture of FAs characteristic of erythrocytes.
Results are given as relative amounts of EPA (C20:5n3) and DHA
(C22:6n3), expressed as a percentage of a total of 26 identified
FAs, referred to as Omega-3 Index. A validated correction factor
was applied for whole blood aliquots (14, 15). Where mentioned,
ALA (C18:3n3) is given as percentage of a total of 26 identified
FAs. The coefficient of variation for FA levels was 5%. Analyses
were quality controlled according to DIN ISO 15189.
Assessment of Kidney Function,
Albuminuria and Other Biomarkers
Plasma creatinine, Cystatin C and high-sensitivity C-reactive
protein (hs-CRP) were assayed from fresh samples immediately
after blood draw on a Roche Cobas analyzer (F. Hoffmann-La
Roche, Basel, Switzerland). Estimated glomerular filtration rate
(eGFR) given asmL/min /1.73m2 was computed using the CKD-
EPI Creatinine-Cystatin Equation (2012) as published by Inker et
al. (16). Urine albumin and urine creatinine were obtained from
fasting morning urine samples. Albuminuria was quantified with
the ACR and given in mg/mmol. Hemoglobin A1c (HbA1c) was
measured using HPLC.
Other Study Variables
For all participants, a detailed assessment of personal, medical,
lifestyle and nutritional factors was performed. Smoking status
was self-assessed and categorized into current, past and never
smokers. Moderate and vigorous physical activity was assessed
using the validated international physical activity questionnaire
(17). Regular physical activity was defined as moderate or
vigorous physical activity of at least 75 or 150 min/week,
respectively. Alcohol consumption and frequency of fruit,
vegetable and fish consumption were obtained with the Swiss
health survey questionnaire from 2007. Healthy diet was defined
as at least five servings of fruits or vegetables per day. Highest
educational status was reported. Weight and height were directly
measured in a standardized way. BMI was calculated by dividing
weight in kg by height in m2.
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Statistical Analysis
Data were tested against a predefined hypothesis, assuming an
inverse association of Omega-3 Index with eGFR and ACR.
Baseline characteristics were presented overall as well as stratified
according to quartiles of Omega-3 Index in % (medians with
upper and lower quartiles and p-values from Wilcoxon-Mann-
Whitney or chi-squared tests). To assess the relationship of
n-3 PUFAs with eGFR we fit simple and multivariable linear
regression models with eGFR as the dependent variable.
To account for the skewed distribution and excess of zeros
in ACR, we fit a generalized linear model using the Tweedie
distribution and a log-link. Model coefficients were back-
transformed by exponentiation and expressed as ratio. Six outlier
observations with very high ACR (ranging from 79.77 to 104.22,
see Supplementary Table 3) were excluded from the analysis
as values were highly pathological and atypical for this set of
healthy subjects.
For all fitted linear models, we assessed model assumptions
(linearity, normality of residuals, and presence of influential
values); all assumptions held true.
In addition, we evaluated the association of Omega-3, ALA,
EPA and DHA with different eGFR quantiles to study the
potential influence on people with high or low eGFR. We
performed joint multivariate quantile regression using the
method by Yang and Tokdar (18) implemented in the R




Baseline characteristics for the whole population and stratified by
quartiles of the Omega-3 Index are shown in Table 1. Median
age was 37 years (IQR 31; 40) and 53% were female. Median
Omega-3 Index was 4.59 (IQR 4.06; 5.25). Median eGFR was 111
ml/min/1.73m2 (IQR 103; 118). Median ACRwas 0.14mg/mmol
(IQR 0; 0.43).
Participants in the higher Omega-3 Index quartiles had
significantly lower Cystatin C (p < 0.001). Further, a higher
Omega-3was found in women than men and associated with a
lower BMI, less smoking (p-value for all <0.001) and a lower
24-h blood pressure profile (systolic p < 0.0001; diastolic p <
0.001). Additionally, individuals with a higher Omega-3 Index
had higher HDL levels (p < 0.001), lower triglycerides (p <
0.001) and consumed significantly more fruits and vegetables
(p < 0.001) as well as fish (p < 0.001). Groups with a higher
Omega-3 Index also had a higher educational status (p < 0.001).
Inverse Association of Omega-3 Index With
ACR
Omega-3 Index was inversely associated with ACR before and
after adjustment for potential confounders (Table 2). A 1-unit
increase in the Omega-3 Index was associated with a 14% lower
ACR (adjusted ratio 0.86, CI 0.74–1.00; p = 0.048). Analyses of
individual fatty acids showed a significant association for DHA
with a ratio of (0.82, CI 0.68–0.99, p = 0.037) but not for ALA
(p= 0.69) or EPA (p= 0.40), as presented in Table 2.
No Association of Omega-3 Index With
eGFR
In linear regression analyses, no association between the Omega-
3 Index and eGFR was found (Table 3); the adjusted difference
in eGFR was −0.21 ml/min (95%-CI −0.76;0.35; p = 0.466)
per 1-unit increase in Omega-3 Index. Additional analyses
for individual fatty acids (ALA, EPA and DHA) also showed
no significant association with eGFR (Table 3). Moreover, no
significant association was found in non-linear additive models
(Supplementary Material).
DISCUSSION
Our main findings collectively indicate that n-3 FA intake,
as reliably reflected by the Omega-3 Index, is inversely
associated with ACR in young and healthy individuals with
preserved eGFR. Thus, Omega-3 fatty acids may exhibit cardio-
and nephroprotective effects in healthy individuals through
modulation of the ACR.
Albuminuria is a well-established early marker not
only for kidney damage but also as a cardiovascular risk
factor. Both prospective and epidemiologic data support
albuminuria as a predictor for cardiovascular morbidity
and mortality as well as all-cause mortality (6)—not only
in individuals already suffering from hypertension or
diabetes, but also in the general population. Even a minimal
increase in ACR is associated with an increased risk of
kidney failure and cardiovascular disease (19). Moreover,
an increased ACR predicts incident hypertension and
cardiovascular disease mortality at an 11-year follow-
up, highlighting its potential as a target for preventive
interventions (20).
In CKD treatment, the reduction of albuminuria remains a
central pillar. Concerning the effects of n-3 PUFAs, longitudinal,
interventional studies focusing on healthy adults with preserved
kidney function, where prevention measures could be of
particular importance are not available (21). From an
interventional perspective, Elajami et al. (10) showed, that
EPA and DHA supplementation was able to attenuate the
progression of established albuminuria in patients with type 2
diabetes mellitus and coronary artery disease, most of whom
were already under treatment with angiotensin-converting
enzyme inhibitors or angiotensin-receptor blockers.
There is increasing evidence, that Omega-3 fatty acids are
crucial in resolving inflammatory responses as substrates for
the endogenic production of specialized pro-resolving mediators
(resolvins, protectins, and maresins)—stopping inflammation
and giving way to tissue reparation (22, 23). Priante et
al. (24) provided a number of mechanism how n-3 PUFAs
counteract renal inflammation and fibrosis. Further, n-3 PUFA
supplementation affects cell junctions and protects from distal
tubular cell damage in rat kidneys, thus directly and indirectly
affecting albuminuria (25, 26). There is increasing evidence for
differing individual effects of EPA and DHA on cardiometabolic
risk factors (27). In our collective, the inverse association
of n-3 PUFAs with ACR was mainly driven by DHA.



































Omega-3 index range (%) 4.59 [4.06, 5.25] 2.43–4.06 4.08–4.59 4.60–5.25 5.26–9.26
ALA (%) 0.23 [0.18,0.28] 0.22 [0.17,0.28] 0.23 [0.18,0.28] 0.23 [0.19,0.28] 0.24 [0.19,0.29]
EPA (%) 0.62 [0.49, 0.78] 0.5 [0.41, 0.61] 0.57 [0.48, 0.68] 0.64 [0.53, 0.78] 0.8 [0.68, 1.06]
DHA (%) 3.08 [2.62, 3.61] 2.37 [2.17, 2.54] 2.87 [2.73, 3.02] 3.34 [3.18, 3.5] 4.01 [3.78, 4.4]











eGFR (ml/min) 110.88 [102.74, 118.27] 111.09 [102.79, 118.39] 110.32 [103,117.77] 110.47 [102.52, 117.78] 111.79 [102.5, 119.39] 0.60
ACR (mg/mmol) 0.14 [0, 0.43] 0.2 [0, 0.44] 0.19 [0, 0.46] 0 [0, 0.41] 0 [0, 0.37] < 0.01
ACR >3.0 mg/mmol 59 (3%), 19 (4%), 16 (3%), 13 (3%), 11 (2%), 0.50
Cystatin C Serum (mg/l) 0.79 [0.71, 0.87] 0.8 [0.72, 0.88] 0.79 [0.72, 0.87] 0.79 [0.72, 0.86] 0.76 [0.7, 0.85] < 0.001
Creatinine Serum (mg/dl) 0.76 [0.66, 0.87] 0.77 [0.66, 0.88] 0.77 [0.67, 0.87] 0.76 [0.66, 0.87] 0.76 [0.64, 0.87] 0.48

























































24-h DBP (mmHg) 78.13 [73.08, 83.41] 79.09 [73.59, 85.15] 78.41 [73.41, 83.53] 77.84 [72.78, 82.55] 76.79 [72.22, 82.2] < 0.001
24-h SBP (mmHg) 122.56 [115.11, 130.71] 124.39 [116.54, 133.31] 123.06 [115.26, 130.58] 122.28 [115.18, 130.05] 120.3 [113.65, 128.35] < 0.001
Gly HbA1c (%) 5.4 [5.2, 5.6] 5.5 [5.2, 5.7] 5.4 [5.2, 5.6] 5.4 [5.2, 5.6] 5.4 [5.1, 5.6] 0.26
HDL (mmol/l) 1.5 [1.24, 1.79] 1.42 [1.17, 1.71] 1.49 [1.22, 1.76] 1.51 [1.24, 1.84] 1.58 [1.35, 1.86] < 0.001
LDL (mmol/l) 2.87 [2.35, 3.47] 2.98 [2.36, 3.6] 2.87 [2.38, 3.45] 2.88 [2.33, 3.47] 2.72 [2.28, 3.38] 0.05
Triglyceride (mmol/l) 0.84 [0.59,1.19] 0.98 [0.64,1.46] 0.87 [0.62, 1.21] 0.84 [0.59, 1.13] 0.75 [0.57, 1.02] < 0.001
n = 2,001; Data are medians [interquartile range] or numbers (percentages). Regular physical activity = moderate (≥150min per week) or vigorous physical activity (≥75min per week). Fruit and vegetable consumption = fruit and
vegetable consumption ≥5 servings per day. For education h = high, m = middle, l= low. BMI = body mass index, BP = blood pressure, f = female, h = hour, HDL = high density lipoprotein, hs-CRP = high-sensitivity C-reactive
protein, LDL = low density lipoprotein, m = male. *p-value was calculated using analysis of variance, Kruskal-Wallis test (due to asymmetry in most continuous variables) or chi-square test, as appropriate, in order to compare the
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TABLE 2 | Crude and adjusted change in ACR for Omega-3 Index, ALA, EPA and DHA.
Crude ratio (95% CI) P-value Adjusted ratio (95% CI) P-value
Omega-3 Index (per unit [%]) 0.84 (0.73–0.96) 0.011 0.86 (0.74–1.00) 0.048
ALA (per unit [%]) 3.79 (0.97–14.76) 0.055 1.35 (0.30–6.03) 0.692
EPA (per unit [%]) 0.70 (0.42–1.16) 0.165 0.80 (0.47–1.35) 0.401
DHA (per unit [%]) 0.80 (0.67–0.95) 0.011 0.82 (0.68–0.99) 0.037
Covariates used for adjustment are age, sex, BMI, smocking status, mean systolic blood pressure over 24 h, triglycerides, glycated hemoglobin A1c, high density lipoproteins.
Bold values represent that p < 0.05.
TABLE 3 | Crude and adjusted difference in eGFR for Omega-3 Index, ALA, EPA, and DHA.
Crude difference (95% CI) P-value Adjusted difference (95% CI) P-value
Omega-3 Index (per unit [%]) −0.07 (−0.61 to 0.46) 0.794 −0.21 (−0.76 to 0.35) 0.466
ALA (per unit [%]) −1.81 (−7.46 to 3.84) 0.530 −0.72 (−6.58 to 5.15) 0.811
EPA (per unit [%]) 0.70 (−1.23 to 2.63) 0.476 1.49 (−0.51 to 3.49) 0.144
DHA (per unit [%]) −0.20 (−0.88 to 0.48) 0.571 −0.50 (−1.21 to 0.20) 0.162
Covariates used for adjustment were age, sex, BMI, smoking status, mean systolic blood pressure over 24 h, triglycerides, glycated hemoglobin A1c and high-density lipoproteins.
Accordingly, several mechanistic studies provided evidence for
DHA suppressing inflammation pathways in the kidney—of note,
oxygenated metabolites were decreased more effectively by DHA
than EPA (28–30).
The observed inverse association of Omega-3 fatty acids
with ACR is concordant with a multitude of well-established
beneficial effects of n-3 fatty acids on the cardiovascular system
(31). Hypertension, oxidative stress, dyslipidemia, endothelial
dysfunction and thrombogenesis are all intermediaries in the
pathogenesis of both kidney disorders and cardiovascular
disease—and all are positively modifiable through n-3 PUFAs
(21, 32, 33). As already shown earlier by our group, omega-3
fatty acids are inversely associated with blood pressure in the
same, mostly normotensive population, which may be a driver
for kidney damage in young and healthy individuals (4). Further,
participants with more favorable fatty acid profile at baseline
have significantly lower triglyceride and higher HDL levels. The
decreased risk of ischemic events through n-3 PUFA mediated
triglyceride level modification was impressively demonstrated in
the REDUCE-IT trial, where very high dosages of n-3 PUFAS
were administrated (34). In contrast, the median Omega-3 Index
of 4.6% in our population is highly comparable to data from
other Western countries with an average Index of 4–5% (35–
37), but still well-below the 8% recommended for optimal
cardioprotection (14) or countries with high fish consumption
like Japan (Omega-3 Index between 8 and 10%) (38). This
suggests, that in the measured range of our population, no
specific lower n-3 threshold exists. As demonstrated in the
JELIS trial for major coronary event, n-3 PUFA is likely to
be a continuous beneficial variable, where no ceiling effect
was observed (39). Both, more favorable lipid profiles as well
as lower blood pressure might mediate the observed effects.
Further, participants with a higher Omega-3 Index are better
educated, eat healthier and do more exercise. Nevertheless,
our results remained significant also after adjustment for
potential confounders.
Concerning the effect of n-3 PUFAs on eGFR, Miller et al.
(40) suggest in their metanalysis that n-3 PUFA supplementation
reduces urine protein excretion but not decline in GFR. While
also in our population no association of Omega-3 Index with
eGFR could be found, one should consider several factors
when interpreting these results: First, the CKD-EPI formula,
as all other formulas calculating the glomerular filtration rate,
remains an estimation. Especially in patients with preserved
eGFR, this estimation becomes less accurate and may not detect
fine differences between individuals (41). Further, a quantifiable
reduction in eGFR is a sign of significant and advanced kidney
damage—not to be expected in this cohort of generally young
and healthy adults. However, Cystatin C as a probably superior
predictor of GFR in individuals with normal andmildly impaired
kidney function (42) significantly differed across Omega-3 Index
quartiles at baseline. This could also be explained with effects, in
contrast to ACR findings, only grasping with higher n-3 PUFA
levels—reflected in the drop of Cystatin C in the highest Omega-3
Index quartile. Interestingly, an analysis of the serum n-3 PUFA,
creatinine and Cystatin C levels in 549 Japanese community-
dwellers by Higashiyama et al. (43) found an association of n-3
PUFA fatty acids with Cystatin C based but not creatinine based
eGFR estimation. Whether higher Omega-3 fatty acid levels may
have a preventive effect on physiologic (accelerated) decline in
kidney function is to be determined in longitudinal studies.
The main strengths of our study include the availability
of both creatinine and cystatin C for the computation of the
eGFR, which permitted us to implement the internationally
recognized combined CKD-EPI formula (16). Additionally, we
utilized the still novel Omega-3 Index as a marker for n-3 PUFA
intake. This method is proven to have a reduced biologic and
analytic variability compared to plasma levels and thus reliably
reflects and individual’s long-term omega-3 status and tissue
content (12). It is robust and resistant to short-term variation
of n-3 PUFA intake and obviously superior to often unreliable
nutritional questionnaires (13). Together with definition and
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homogeneity of our large and well-characterized study cohort
composed of the young and healthy population of Liechtenstein
with access to state-of-the-art preventive and medical service,
it allows comparability to other Western societies. Further,
we were careful to exclude individuals with known renal
insufficiency, on ARBs as well as ACEs or suffering from any
major illness including diabetes—thus allowing to minimize
residual confounding.
Limitations include the cross-sectional design not allowing
to infer causal relationship or to determine the directionality of
the observed effects. Also, residual confounding despite extensive
adjustment cannot be completely ruled out. Our findings are
also limited to the observed population (white, affluent young
and healthy) with its specific characteristics including usually
healthy nutritional habits. Further, the use of single spot-urine
after an overnight fast, rather than repeated measurements
or the gold-standard of 24-h collection may have influenced
our results for albuminuria. Fourth, none of the results were
adjusted for multiple testing, given a clear, predefined hypothesis
and to avoid potential over-adjustment because of significant
correlations between individual fatty acids. Lastly, we do not have
data on the source of n-3 PUFAs or the number of individuals
taking supplements. The latter is likely to be very low given the
relatively low levels of the n-3 concentrations measured, as also
shown in a study by Shen et al. (44) linking measured Omega-
3 Index levels to self-reported fatty acid intake. Overall, detailed
information on the n-3 PUFA source is probably not of relevance
to the association, with the Omega-3 Index representing an active
biologic analog (independent of data on the form and frequency
of intake).
In conclusion, a higher Omega-3 Index was significantly
associated with a lower ACR in this cohort of young healthy
individuals with preserved GFR. In addition to cardiovascular
preventive properties, Omega-3 fatty acids may have a protective
effect on early kidney injury. The supplementation and/or higher
intake of n-3 PUFAs may provide a well-tolerated, cost-effective
approach for the prevention of chronic kidney disease—another
established cardiovascular risk factor with its own substantial
burden of disease and socioeconomic footprint.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Cantonal Ethics Commission of Zurich, Zurich,
Switzerland. The patients/participants provided their written
informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
MF, DC, and JB contributed to the conception or design of the
work. All authors contributed to the acquisition, analysis, or
interpretation of data for the work. MF drafted the manuscript.
SA, SR, MRe, DC, and JB critically revised the manuscript. All
gave final approval and agree to be accountable for all aspects of
work ensuring integrity and accuracy.
FUNDING
The GAPP study was supported by the Liechtenstein
Government, the Swiss Heart Foundation, the Swiss Society of
Hypertension, the University of Basel, the University Hospital
Basel, the Hanela Foundation, Schiller AG and Novartis. The
Swiss National Science Foundation supported the current
sub-study (grant no. 310030_144152/1 to JB) as well as the
Swiss Heart Foundation, the Foundation Kardio, Baden,
Switzerland and the Cantonal Hospital of Baden. DC holds
a McMaster University Department of Medicine Mid-Career
Research Award.
SUPPLEMENTARY MATERIAL




1. Holy EW, Forestier M, Richter EK, Akhmedov A, Leiber F, Camici GG, et
al. Dietary α-linolenic acid inhibits arterial thrombus formation, tissue factor
expression, and platelet activation. Arterioscler Thromb Vasc Biol. (2011)
31:1772–80. doi: 10.1161/ATVBAHA.111.226118
2. Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J, et al. Effect of
omega-3 fatty acids supplementation on endothelial function: a meta-
analysis of randomized controlled trials. Atherosclerosis. (2012) 221:536–
43. doi: 10.1016/j.atherosclerosis.2012.01.006
3. Nestel P, Clifton P, Colquhoun D, Noakes M, Mori TA, Sullivan D, et
al. Indications for Omega-3 long chain polyunsaturated fatty acid in the
prevention and treatment of cardiovascular disease. Heart Lung Circ. (2015)
24:769–79. doi: 10.1016/j.hlc.2015.03.020
4. Filipovic MG, Aeschbacher S, Reiner MF, Stivala S, Gobbato S, Bonetti N, et
al. Whole blood omega-3 fatty acid concentrations are inversely associated
with blood pressure in young, healthy adults. J Hypertens. (2018) 36:1548–
54. doi: 10.1097/HJH.0000000000001728
5. Pun PH. The interplay between chronic kidney disease, sudden cardiac
death, and ventricular arrhythmias. Adv Chronic Kidney Dis. (2014) 21:480–
8. doi: 10.1053/j.ackd.2014.06.007
6. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated
glomerular filtration rate and albuminuria for prediction of cardiovascular
outcomes: a collaborative meta-analysis of individual participant data.
Lancet Diabetes Endocrinol. (2015) 3:514–25. doi: 10.1016/S2213-8587(15)
00040-6
7. Baggio B, Musacchio E, Priante G. Polyunsaturated fatty acids and renal
fibrosis: pathophysiologic link and potential clinical implications. J Nephrol.
(2005) 18:362–7.
8. Hagiwara S, Makita Y, Gu L, Tanimoto M, Zhang M, Nakamura S,
et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2
diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased
Frontiers in Cardiovascular Medicine | www.frontiersin.org 6 April 2021 | Volume 8 | Article 622619
Filipovic et al. The Omega-Kid Study
ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant. (2006) 21:605–
15. doi: 10.1093/ndt/gfi208
9. Lauretani F, Semba RD, Bandinelli S, Miller ER, Ruggiero C, Cherubini
A, et al. Plasma polyunsaturated fatty acids and the decline of renal
function. Clin. Chem. (2008) 54:475–81. doi: 10.1373/clinchem.2007.
095521
10. Elajami TK, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M,
Welty FK. Eicosapentaenoic and docosahexaenoic acids attenuate progression
of albuminuria in patients with type 2 diabetes mellitus and coronary
artery disease. J Am Heart Assoc. (2017) 6:247. doi: 10.1161/JAHA.116.
004740
11. Conen D, Schön T, Aeschbacher S, Paré G, Frehner W, Risch M,
et al. Genetic and phenotypic determinants of blood pressure and
other cardiovascular risk factors (GAPP). Swiss Med Wkly. (2013)
143:w13728. doi: 10.4414/smw.2013.13728
12. Schacky C von. The Omega-3 Index as a risk factor for
cardiovascular diseases. Prostaglandins Other Lipid Mediat. (2011)
96:94–8. doi: 10.1016/j.prostaglandins.2011.06.008
13. Harris WS, Schacky C von. The Omega-3 Index: a new risk factor
for death from coronary heart disease? Prev Med. (2004) 39:212–
20. doi: 10.1016/j.ypmed.2004.02.030
14. Harris WS. The omega-3 index: clinical utility for therapeutic intervention.
Curr Cardiol Rep. (2010) 12:503–8. doi: 10.1007/s11886-010-0141-6
15. William S Harris, Jason Polreis. Measurement of the Omega-3 Index in
dried blood spots. Ann Clin Lab Res. (2016) 4:4. doi: 10.21767/2386-5180.
1000137
16. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene
T, et al. Estimating glomerular filtration rate from serum creatinine
and cystatin C. N Engl J Med. (2012) 367:20–9. doi: 10.1056/NEJMoa
1114248
17. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML,
Ainsworth BE, et al. International physical activity questionnaire:
12-country reliability and validity. Med Sci Sports Exerc. (2003)
35:1381–95. doi: 10.1249/01.MSS.0000078924.61453.FB
18. Tokdar S, Cunningham E. Qrjoint: Joint Estimation in Linear Quantile
Regression (2018).
19. Association of estimated glomerular filtration rate and albuminuria
with all-cause and cardiovascular mortality in general population
cohorts: a collaborative meta-analysis. Lancet. (2010) 375:2073–
81. doi: 10.1016/S0140-6736(10)60674-5
20. Sung K-C, Ryu S, Lee J-Y, Lee SH, Cheong E, Hyun Y-Y, et al.
Urine albumin/creatinine ratio below 30 mg/g is a predictor of incident
hypertension and cardiovascular mortality. J Am Heart Assoc. (2016)
5:e003245. doi: 10.1161/JAHA.116.003245
21. Lee CC, Adler AI. Recent findings on the effects of marine-derived n-
3 polyunsaturated fatty acids on urinary albumin excretion and renal
function. Curr Atheroscler Rep. (2012) 14:535–41. doi: 10.1007/s11883-012-
0279-3
22. Doyle R, Godson C, Brennan E. Promoting resolution in kidney disease:
are we nearly there yet? Curr Opin Nephrol Hypertens. (2020) 29:119–
27. doi: 10.1097/MNH.0000000000000558
23. Mendivil CO. Dietary fish, fish nutrients, and immune function: a review.
Front Nutr. (2020) 7:617652. doi: 10.3389/fnut.2020.617652
24. Priante G, Musacchio E, Valvason C, Clari G, Bordin L, Sartori L, Baggio
B. Further insights about the beneficial effects of n-3 fatty acids in the
early molecular events of renal fibrosis in vitro. J Nephrol. (2013) 26:652–
9. doi: 10.5301/jn.5000193
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